Oppenheimer Asset Management Inc. Takes Position in Artivion, Inc. $AORT

Oppenheimer Asset Management Inc. purchased a new stake in shares of Artivion, Inc. (NYSE:AORT) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 21,513 shares of the company’s stock, valued at approximately $669,000. Oppenheimer Asset Management Inc. owned approximately 0.05% of Artivion at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in AORT. MCF Advisors LLC lifted its holdings in shares of Artivion by 109.3% in the first quarter. MCF Advisors LLC now owns 1,176 shares of the company’s stock worth $29,000 after buying an additional 614 shares in the last quarter. EntryPoint Capital LLC purchased a new position in Artivion in the 1st quarter worth $284,000. Natixis Advisors LLC raised its position in Artivion by 16.4% in the 1st quarter. Natixis Advisors LLC now owns 12,615 shares of the company’s stock worth $310,000 after purchasing an additional 1,777 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Artivion by 18.9% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,358 shares of the company’s stock worth $353,000 after buying an additional 2,285 shares during the period. Finally, Diker Management LLC purchased a new position in Artivion in the 1st quarter worth approximately $369,000. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Analyst Upgrades and Downgrades

AORT has been the topic of a number of research analyst reports. Citigroup restated an “outperform” rating on shares of Artivion in a report on Friday, October 10th. Needham & Company LLC raised their price objective on Artivion from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Friday, August 22nd. LADENBURG THALM/SH SH downgraded shares of Artivion from a “buy” rating to a “neutral” rating and raised their price target for the company from $32.00 to $38.80 in a research report on Wednesday, August 13th. Canaccord Genuity Group lifted their price target on shares of Artivion from $41.00 to $50.00 and gave the stock a “buy” rating in a research note on Monday, September 29th. Finally, Stifel Nicolaus boosted their price target on Artivion from $40.00 to $46.00 and gave the company a “buy” rating in a research note on Monday, September 29th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Artivion presently has an average rating of “Moderate Buy” and a consensus target price of $43.97.

Artivion Stock Down 0.5%

AORT opened at $45.41 on Friday. The firm has a 50-day simple moving average of $42.21 and a two-hundred day simple moving average of $34.68. Artivion, Inc. has a 52 week low of $21.97 and a 52 week high of $46.19. The company has a market capitalization of $2.14 billion, a PE ratio of -108.12 and a beta of 1.67. The company has a quick ratio of 3.48, a current ratio of 4.78 and a debt-to-equity ratio of 0.52.

Artivion (NYSE:AORT) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.24 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.13. The company had revenue of $112.97 million during the quarter, compared to analyst estimates of $107.96 million. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.Artivion’s revenue was up 15.3% on a year-over-year basis. Artivion has set its FY 2025 guidance at EPS. Analysts forecast that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Insider Buying and Selling at Artivion

In other Artivion news, SVP Jean F. Holloway sold 23,356 shares of the stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $43.01, for a total transaction of $1,004,541.56. Following the completion of the transaction, the senior vice president owned 172,129 shares in the company, valued at $7,403,268.29. This trade represents a 11.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Marshall S. Stanton sold 18,200 shares of the stock in a transaction dated Wednesday, August 27th. The shares were sold at an average price of $44.02, for a total transaction of $801,164.00. Following the completion of the transaction, the senior vice president directly owned 64,200 shares of the company’s stock, valued at approximately $2,826,084. The trade was a 22.09% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 74,858 shares of company stock worth $3,250,129 over the last three months. 7.60% of the stock is owned by company insiders.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.